First Time Loading...

Amneal Pharmaceuticals Inc
NYSE:AMRX

Watchlist Manager
Amneal Pharmaceuticals Inc Logo
Amneal Pharmaceuticals Inc
NYSE:AMRX
Watchlist
Price: 6.87 USD 0.29% Market Closed
Updated: May 16, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

3.5B
-6%
Assets
Growth Rates:
1 Year
-9%
3 Years
-13%
5 Years
-20%
7 Years
+90%
10 Years
+248%
3.5B
+3%
Liabilities
Growth Rates:
1 Year
-1%
3 Years
-7%
5 Years
-10%
7 Years
+188%
10 Years
+1 749%
19.8m
-94%
Equity
Growth Rates:
1 Year
-93%
3 Years
-93%
5 Years
-96%
7 Years
-97%
10 Years
-98%

Balance Sheet Decomposition
Amneal Pharmaceuticals Inc

3.5B
Assets
3.5B
Liabilities
3.5B
Assets
3.5B
Liabilities
Current Assets 1.4B
Cash & Short-Term Investments 91.5m
Receivables 645.7m
Other Current Assets 640.7m
Non-Current Assets 2.1B
PP&E 550.1m
Intangibles 1.5B
Other Non-Current Assets 55.5m
Current Liabilities 846.6m
Accounts Payable 143.6m
Accrued Liabilities 403.1m
Short-Term Debt 179m
Other Current Liabilities 120.9m
Non-Current Liabilities 2.6B
Long-Term Debt 2.5B
Other Non-Current Liabilities 120.2m

Balance Sheet
Amneal Pharmaceuticals Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
215
340
180
182
213
151
341
248
26
92
Cash Equivalents
215
340
180
182
213
151
341
248
26
92
Short-Term Investments
200
0
0
0
0
0
0
0
0
0
Total Receivables
147
325
257
302
529
636
674
728
797
646
Accounts Receivables
147
325
257
241
482
604
639
663
742
614
Other Receivables
0
0
0
61
47
32
35
65
55
32
Inventory
81
126
175
159
457
381
491
489
531
581
Other Current Assets
34
32
18
53
87
42
45
55
58
59
Total Current Assets
676
822
631
696
1 287
1 210
1 552
1 520
1 412
1 378
PP&E Net
188
214
233
125
544
620
605
639
589
550
PP&E Gross
188
214
233
125
544
620
605
639
589
550
Accumulated Depreciation
116
133
156
116
209
276
332
395
446
508
Intangible Assets
27
602
621
263
1 655
1 383
1 305
1 167
1 096
890
Goodwill
28
210
207
207
426
420
523
593
599
599
Other Long-Term Assets
161
74
131
61
441
33
22
21
103
56
Other Assets
28
210
207
207
426
420
523
593
599
599
Total Assets
1 079
N/A
1 923
+78%
1 823
-5%
1 351
-26%
4 353
+222%
3 666
-16%
4 006
+9%
3 940
-2%
3 799
-4%
3 473
-9%
Liabilities
Accounts Payable
32
56
59
81
115
102
151
189
166
144
Accrued Liabilities
126
270
245
248
400
410
464
404
383
403
Short-Term Debt
0
0
0
0
0
0
0
0
60
179
Current Portion of Long-Term Debt
0
0
18
18
22
24
48
34
33
37
Other Current Liabilities
1
1
0
7
18
15
13
50
110
84
Total Current Liabilities
159
327
321
354
554
550
677
677
753
847
Long-Term Debt
0
425
814
770
2 670
2 675
2 834
2 778
2 692
2 486
Deferred Income Tax
0
73
0
3
1
0
0
0
0
0
Minority Interest
0
0
0
0
392
115
54
24
89
42
Other Liabilities
33
36
64
37
232
94
138
100
145
79
Total Liabilities
191
N/A
860
+350%
1 199
+39%
1 164
-3%
3 848
+231%
3 434
-11%
3 703
+8%
3 579
-3%
3 501
-2%
3 453
-1%
Equity
Common Stock
1
1
1
1
3
3
3
3
3
3
Retained Earnings
531
570
98
372
21
378
287
276
406
490
Additional Paid In Capital
364
504
535
560
530
607
628
658
692
539
Treasury Stock
2
2
2
2
0
0
0
0
0
0
Other Equity
6
11
8
1
8
0
41
25
10
32
Total Equity
888
N/A
1 062
+20%
624
-41%
187
-70%
505
+170%
232
-54%
303
+31%
360
+19%
298
-17%
20
-93%
Total Liabilities & Equity
1 079
N/A
1 923
+78%
1 823
-5%
1 351
-26%
4 353
+222%
3 666
-16%
4 006
+9%
3 940
-2%
3 799
-4%
3 473
-9%
Shares Outstanding
Common Shares Outstanding
71
73
74
74
299
299
300
302
304
459
Preferred Shares Outstanding
0
0
0
0
0
0
0
0
0
0

See Also

Summary
AMRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMRX stock valuation using valuation multiples.
Wall Street Estimates
AMRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.